Psych journal discloses financial ties

The editor in chief of Psychiatric Times, a leading psychiatric journal, has stepped forward to say the journal will disclose conflicts of interest of its editorial board to "help ensure fair and accurate reporting, as well as balanced and scientifically grounded opinion and commentary." Some board members have ties to universities and drugmakers. The Integrity in Science Watch program and The International Committee of Medical Journal Editors also weigh in on the disclosure topic. 

There has been a lot of hand-wringing over inappropriate industry influence on psychiatrists, as psychiatry and pharma often work closely on clinical trials and drug education. Critics say docs need to disclose and cut down on these ties, while others say partnerships with drugmakers benefit patients, as long as researchers follow their institutions' conflict of interest rules.

- read the Pharmalot report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.